

REGISTERED NUMBER: 08277417 (England and Wales)

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

FOR

PUMA BIOTECHNOLOGY LTD

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

PUMA BIOTECHNOLOGY LTD
COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2020

DIRECTOR: A Auerbach

REGISTERED OFFICE: 11th Floor
Whitefriars
Lewins Mead
Bristol
BS1 2NT

REGISTERED NUMBER: 08277417 (England and Wales)

AUDITORS: WD Audit Limited
Lower Ground Floor
111 Charterhouse Street
London
EC1M 6AW

BALANCE SHEET
31 DECEMBER 2020

	Notes	2020 £	2019 £
CURRENT ASSETS			
Debtors	4	32,033	27,593
Cash at bank		<u>6,038</u>	<u>5,819</u>
		38,071	33,412
CREDITORS			
Amounts falling due within one year	5	<u>(3,439)</u>	<u>(2,027)</u>
NET CURRENT ASSETS		<u>34,632</u>	<u>31,385</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>34,632</u>	<u>31,385</u>
CAPITAL AND RESERVES			
Called up share capital		3	3
Retained earnings		<u>34,629</u>	<u>31,382</u>
		<u>34,632</u>	<u>31,385</u>

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 22 September 2021 and were signed by:

A Auerbach - Director

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

1. STATUTORY INFORMATION

Puma Biotechnology Ltd is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover represents income earned from the parent, Puma Biotechnology Inc. based on a cost plus agreement, excluding Value Added Tax.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognized in the Income Statement, except to the extent that it relates to items recognized in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognized at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2019 - 2) .

4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020	2019
	£	£
Amounts owed by group undertakings	31,499	27,341
VAT	512	252
Deferred tax asset	<u>22</u>	<u>-</u>
	<u>32,033</u>	<u>27,593</u>

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2020**

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020	2019
	£	£
Tax	569	419
Social security and other taxes	1,420	308
Accrued expenses	<u>1,450</u>	<u>1,300</u>
	<u>3,439</u>	<u>2,027</u>

6. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Roy Davis (Senior Statutory Auditor)
for and on behalf of WD Audit Limited

7. RELATED PARTY DISCLOSURES

The company is a wholly owned subsidiary of Puma Biotechnology, Inc.

During the period the company invoiced services to its parent company, Puma Biotechnology, Inc., amounting to £56,852 (2019: £86,355).

As at 31 December 2020 an amount of £31,499 (2019: £27,341) was owed to the company from Puma Biotechnology, Inc.

8. ULTIMATE CONTROLLING PARTY

The ultimate controlling party is Puma Biotechnology, Inc. Incorporated in the state of Delaware, USA with the registered address 10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA 90024.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.